Latest Commercialisation News

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Eden Innovations is investing in new R&D equipment to enhance its carbon nanotube concrete technology, targeting the booming AI data centre market with improved heat dissipation and electromagnetic shielding.

Firebird Metals has locked in exclusive global rights to five critical LMFP patents, solidifying its position in the lithium-ion battery materials market and paving the way for its Australian Demonstration Plant.

Australia’s ANSTO has independently confirmed that Lindian Resources’ Kangankunde monazite concentrate is exempt from radioactive transport classification, simplifying export logistics and lowering downstream costs.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

FortifAI Limited reported a 51% revenue decline but a 70% reduction in net loss for H1 FY26, alongside completing a major AI technology acquisition and securing $5 million in fresh capital.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.